Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 15/20 | 0.71 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.50 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30194820 | 0.85 | FOLH1 (0.48) | FOLH1 | |
| SCHEMBL10430532 | 0.84 | FOLH1 (0.61) | FOLH1GRM3NAALAD2 | |
| SCHEMBL28640 | 0.83 | FOLH1 (1.00) | FOLH1GRM3NAALAD2 | |
| SCHEMBL2148222 | 0.83 | FOLH1 (0.65) | FOLH1GRM3NAALAD2CYP1A2 | |
| SCHEMBL15305176 | 0.82 | FOLH1 (0.71) | FOLH1GRM3NAALAD2 | |
| SCHEMBL12993346 | 0.82 | FOLH1 (0.71) | FOLH1GRM3NAALAD2 | |
| SCHEMBL3698857 | 0.82 | FOLH1 (0.71) | FOLH1GRM3NAALAD2 | |
| SCHEMBL30452229 | 0.81 | FOLH1 (0.95) | FOLH1GRM3NAALAD2 | |
| SCHEMBL30194708 | 0.81 | CA2 (0.48) | FOLH1 | |
| SCHEMBL29506667 | 0.81 | FOLH1 (0.95) | FOLH1GRM3NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9295728-B2 | Co-polymer conjugates | NITTO DENKO CORPORATION (JP) | 2016-03-29 | — | — | US | disclosed |
| US-20130272993-A1 | CO-POLYMER CONJUGATES | NITTO DENKO CORPORATION (JP) | 2013-10-17 | — | — | US | disclosed |
| US-20090214652-A1 | SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130272993-A1 | CO-POLYMER CONJUGATES | CD44, SLC3A2, SLC7A1 | FOLH1 6/4885GRM3 556/4885NAALAD2 95/4885 |
| US-20090214652-A1 | SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS | MMP1, COL2A1, FN1 | FOLH1 4008/4885GRM3 4641/4885NAALAD2 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.